Drug could prevent type 2 diabetes in high-risk individuals

September 15, 2006

Giving people at high-risk of developing type 2 diabetes a drug called rosiglitazone, along with lifestyle recommendations, could substantially reduce their chances of developing the disease, according to an Online/Article published by The Lancet today (Friday September 15, 2006).

Type 2 diabetes develops when people cannot produce enough of the hormone insulin or when the insulin that their body does make does not work properly. This lack of insulin means they are unable to utilise glucose in the normal way. People with two conditions that impair their regulation of glucose - impaired glucose tolerance or impaired fasting glucose - have a high risk of developing type 2 diabetes. More than 8% of people worldwide have these two conditions, and about 5-10% of these people will develop diabetes every year.

In the DREAM trial, Canadian investigators randomised 5269 adults with impaired glucose tolerance or impaired fasting glucose to receive rosiglitazone or placebo daily for three years. At regular intervals throughout the study the researchers emphasised the importance of a healthy diet and lifestyle to the participants. They found that 280 individuals on rosiglitazone and 658 on placebo developed diabetes. There was a small excess risk of non-fatal heart failure in the drug group when compared to the placebo group.

The authors conclude: "The results of this study suggest that the addition of rosiglitazone to basic lifestyle recommendations substantially reduces the risk of developing diabetes by about two-thirds, offering a novel preventive approach...Balancing both the benefits and the risks suggests that for every 1000 people treated with rosiglitazone for 3 years, about 144 cases of diabetes will be prevented, with an excess of four to five cases of congestive heart failure."
-end-
Contact: Dr Hertzel C Gerstein, DREAM Project Office, Population Health Research Institute (at McMaster University and Hamilton Health Sciences), 237 Barton Street East, 2nd Floor, Hamilton, Ontario, L8L 2X2, Canada, dream@cardio.on.ca or gerstein@mcmaster.ca Dr Gerstein is currently in Copenhagen and can be reached by email.

Notes to editors

The results of the DREAM trial are being presented at the 42nd Annual Meeting of the European Association for the Study of Diabetes in Copenhagen, September 14-17, 2006. The embargo coincides with the presentation.

Lancet

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.